A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

mAbs

Volumn 7, Issue 5, 2015, Pages 946-956

  Piccione, Emily C ^a   Juarez, Silvia ^a   Liu, Jie ^a   Tseng, Serena ^a   Ryan, Christine E ^a   Narayanan, Cyndhavi ^a   Wang, Lijuan ^a   Weiskopf, Kipp ^a   Majeti, Ravindra ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

Bispecific antibody; CD47; Lymphoma; Phagocytosis; Synergy

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIGEN; CD47 ANTIGEN; DOUBLE VARIABLE DOMAIN IMMUNOGLOBULIN; FC RECEPTOR; IMMUNOGLOBULIN; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURFACE PLASMON RESONANCE; ANIMAL; ANTIBODY AFFINITY; DRUG SCREENING; IMMUNOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, CD20; ANTIGENS, CD47; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, NON-HODGKIN; MICE; POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954316938     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1062192     Document Type: Article

References (44)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx. doi. org/10. 1038/nri2744
2. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http://dx. doi. org/10. 4161/mabs. 22976
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57; PMID:16151408; http://dx. doi. org/10. 1038/nbt1137
4. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359:613-26; PMID:18687642; http://dx. doi. org/10. 1056/NEJMra0708875
5. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001; 11:130-5; PMID:11306274; http://dx. doi. org/ 10. 1016/S0962-8924(00)01906-1
6. Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesionmolecule. J Biol Chem 1999; 274:559-62; PMID:9872987; http:// dx. doi. org/10. 1074/jbc. 274. 2. 559
7. Seiffert M, Brossart P, Cant C, CellaM, ColonnaM, Brugger W, Kanz L, Ullrich A, Buhring HJ. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 2001; 97:2741-9; PMID:11313266; http://dx. doi. org/10. 1182/blood. V97. 9. 2741
8. Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol 2006; 6:457-64; PMID:16691243; http://dx. doi. org/ 10. 1038/nri1859
9. Tsai RK, Discher DE. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008; 180:989-1003; PMID:18332220; http://dx. doi. org/ 10. 1083/jcb. 200708043
10. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr., van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99; PMID:19632179; http://dx. doi. org/10. 1016/j. cell. 2009. 05. 045
11. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142:699-713; PMID:20813259; http://dx. doi. org/10. 1016/j. cell. 2010. 07. 044
12. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012; 109:6662-7; PMID:22451913; http://dx. doi. org/10. 1073/pnas. 1121623109
13. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011; 71:1374-84; PMID:21177380; http://dx. doi. org/10. 1158/0008-5472. CAN-10-2238
14. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138:271-85; PMID:19632178; http://dx. doi. org/10. 1016/j. cell. 2009. 05. 046
15. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPalpha Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science 2013. 341:88-91; PMID:23722425; http://dx. doi. org/10. 1126/science. 1238856
16. Theocharides AP, Jin L, Cheng PY, Prasolava TK, Malko AV, Ho JM, Poeppl AG, van Rooijen N, Minden MD, Danska JS, et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 2012; 209:1883-99; PMID:22945919; http://dx. doi. org/10. 1084/jem. 20120502
17. Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012; 24:225-32; PMID:22310103; http://dx. doi. org/ 10. 1016/j. coi. 2012. 01. 010
18. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011; 16:277-306; PMID:21196171; http://dx. doi. org/10. 2741/3688
19. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011; 108:18342-7; PMID:22042861; http://dx. doi. org/10. 1073/pnas. 1106550108
20. Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. Bio-Drugs 2010; 24:89-98; PMID:20199124; http://dx. doi. org/10. 2165/11530960-000000000-00000
21. May C, Sapra P, Gerber HP. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol 2012; 84:1105-12; PMID:22858161; http://dx. doi. org/10. 1016/j. bcp. 2012. 07. 011
22. Fischer N, Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx. doi. org/ 10. 1159/000101046
23. Marvin JS, Zhu Z. Recombinant approaches to IgGlike bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx. doi. org/ 10. 1111/j. 1745-7254. 2005. 00119. x
24. Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993; 90:6444-8; PMID:8341653; http://dx. doi. org/10. 1073/pnas. 90. 14. 6444
25. Deyev SM, Lebedenko EN. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 2008; 30:904-18; PMID:18693269; http://dx. doi. org/10. 1002/bies. 20805
26. Cheong HS, Chang JS, Park JM, Byun SM. Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem Biophys Res Commun 1990; 173:795-800; PMID:1702631; http:// dx. doi. org/10. 1016/S0006-291X(05)80857-5
27. Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246:367-73; PMID:7533215; http://dx. doi. org/10. 1006/jmbi. 1994. 0091
28. Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999; 230:159-71; PMID:10594363; http://dx. doi. org/10. 1016/S0022-1759(99)00135-0
29. Dorvillius M, Garambois V, Pourquier D, Gutowski M, Rouanet P, Mani JC, Pugniere M, Hynes NE, Pelegrin A. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol 2002; 23:337-47; PMID:12677091; http://dx. doi. org/10. 1159/000069793
30. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25; PMID:18841159; http://dx. doi. org/10. 1038/sj. bjc. 6604700
31. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47:107-14; PMID:20350657; http://dx. doi. org/10. 1053/j. seminhematol. 2010. 01. 001
32. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx. doi. org/10. 1038/nbt1345
33. Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339-47; PMID:20068402; http://dx. doi. org/ 10. 4161/mabs. 1. 4. 8755
34. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44:15150-8; PMID:16285718; http://dx. doi. org/10. 1021/bi0511078
35. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108:1975-8; PMID:16705086; http://dx. doi. org/ 10. 1182/blood-2006-04-014639
36. Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007; 47:1725-32; PMID:17725740; http://dx. doi. org/10. 1111/j. 1537-2995. 2007. 01348. x
37. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174:6477-89; PMID:15879151; http://dx. doi. org/10. 4049/jimmunol. 174. 10. 6477
38. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010; 31:212-9; PMID:20452821; http://dx. doi. org/10. 1016/j. it. 2010. 04. 001
39. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell 2012; 10:120-36; PMID:22305562; http://dx. doi. org/ 10. 1016/j. stem. 2012. 01. 006
40. Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs 2013; 5:513-7; PMID:23727858; http://dx. doi. org/10. 4161/mabs. 24990
41. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45; PMID:7506951
42. Gresham HD, Goodwin JL, Allen PM, Anderson DC, Brown EJ. A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J Cell Biol 1989; 108:1935-43; PMID:2785522; http://dx. doi. org/10. 1083/jcb. 108. 5. 1935
43. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52:6761-7; PMID:1458463
44. Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ, Levine BL, June CH, McIvor RS, Blazar BR, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 2006; 107:483-91; PMID:16189271; http://dx. doi. org/10. 1182/blood-2005-05-2133